184 related articles for article (PubMed ID: 26025018)
1. Electronic Health Data for Postmarket Surveillance: A Vision Not Realized.
Moore TJ; Furberg CD
Drug Saf; 2015 Jul; 38(7):601-10. PubMed ID: 26025018
[TBL] [Abstract][Full Text] [Related]
2. Pediatric post-marketing safety systems in North America: assessment of the current status.
McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
[TBL] [Abstract][Full Text] [Related]
3. Drug safety data mining with a tree-based scan statistic.
Kulldorff M; Dashevsky I; Avery TR; Chan AK; Davis RL; Graham D; Platt R; Andrade SE; Boudreau D; Gunter MJ; Herrinton LJ; Pawloski PA; Raebel MA; Roblin D; Brown JS
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):517-23. PubMed ID: 23512870
[TBL] [Abstract][Full Text] [Related]
4. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
[TBL] [Abstract][Full Text] [Related]
5. The utilization and challenges of Japan's MID-NET
Yamada K; Itoh M; Fujimura Y; Kimura M; Murata K; Nakashima N; Nakayama M; Ohe K; Orii T; Sueoka E; Suzuki T; Yokoi H; Ishiguro C; Uyama Y;
Pharmacoepidemiol Drug Saf; 2019 May; 28(5):601-608. PubMed ID: 30945387
[TBL] [Abstract][Full Text] [Related]
6. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.
Nelson JC; Cook AJ; Yu O; Dominguez C; Zhao S; Greene SK; Fireman BH; Jacobsen SJ; Weintraub ES; Jackson LA
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():62-71. PubMed ID: 22262594
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of Prioritizing Drug-Drug-Event Associations Found in Electronic Health Records.
Banda JM; Callahan A; Winnenburg R; Strasberg HR; Cami A; Reis BY; Vilar S; Hripcsak G; Dumontier M; Shah NH
Drug Saf; 2016 Jan; 39(1):45-57. PubMed ID: 26446143
[TBL] [Abstract][Full Text] [Related]
8. A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.
Xu Y; Zhou X; Suehs BT; Hartzema AG; Kahn MG; Moride Y; Sauer BC; Liu Q; Moll K; Pasquale MK; Nair VP; Bate A
Drug Saf; 2015 Aug; 38(8):749-65. PubMed ID: 26055920
[TBL] [Abstract][Full Text] [Related]
9. Improving postapproval drug safety surveillance: getting better information sooner.
Hennessy S; Strom BL
Annu Rev Pharmacol Toxicol; 2015; 55():75-87. PubMed ID: 25292435
[TBL] [Abstract][Full Text] [Related]
10. Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance.
Izem R; Sanchez-Kam M; Ma H; Zink R; Zhao Y
Ther Innov Regul Sci; 2018 Mar; 52(2):159-169. PubMed ID: 29714520
[TBL] [Abstract][Full Text] [Related]
11. Illusions of objectivity and a recommendation for reporting data mining results.
Hauben M; Reich L; Gerrits CM; Younus M
Eur J Clin Pharmacol; 2007 May; 63(5):517-21. PubMed ID: 17364192
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China.
Yang Y; Zhou X; Gao S; Lin H; Xie Y; Feng Y; Huang K; Zhan S
Drug Saf; 2018 Jan; 41(1):125-137. PubMed ID: 28815480
[TBL] [Abstract][Full Text] [Related]
13. Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture?
Coloma PM; Trifirò G; Patadia V; Sturkenboom M
Drug Saf; 2013 Mar; 36(3):183-97. PubMed ID: 23377696
[TBL] [Abstract][Full Text] [Related]
14. Drug makers' adverse event reports are often incomplete, US report finds.
McCarthy M
BMJ; 2015 Feb; 350():h651. PubMed ID: 25652561
[No Abstract] [Full Text] [Related]
15. Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection.
Pacurariu AC; Straus SM; Trifirò G; Schuemie MJ; Gini R; Herings R; Mazzaglia G; Picelli G; Scotti L; Pedersen L; Arlett P; van der Lei J; Sturkenboom MC; Coloma PM
Drug Saf; 2015 Dec; 38(12):1201-10. PubMed ID: 26370104
[TBL] [Abstract][Full Text] [Related]
16. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the quality and value of data sources for postmarket surveillance of the safety of cough and cold medications in children.
Green JL; Reynolds KM; Banner W; Bond GR; Kauffman RE; Palmer RB; Paul IM; Dart RC
BMC Med Res Methodol; 2018 Dec; 18(1):175. PubMed ID: 30577764
[TBL] [Abstract][Full Text] [Related]
18. The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study.
de Bie S; Coloma PM; Ferrajolo C; Verhamme KM; Trifirò G; Schuemie MJ; Straus SM; Gini R; Herings R; Mazzaglia G; Picelli G; Ghirardi A; Pedersen L; Stricker BH; van der Lei J; Sturkenboom MC;
Br J Clin Pharmacol; 2015 Aug; 80(2):304-14. PubMed ID: 25683723
[TBL] [Abstract][Full Text] [Related]
19. Common Models, Different Approaches.
Gagne JJ
Drug Saf; 2015 Aug; 38(8):683-6. PubMed ID: 26088718
[No Abstract] [Full Text] [Related]
20. Structured assessment for prospective identification of safety signals in electronic medical records: evaluation in the health improvement network.
Cederholm S; Hill G; Asiimwe A; Bate A; Bhayat F; Persson Brobert G; Bergvall T; Ansell D; Star K; Norén GN
Drug Saf; 2015 Jan; 38(1):87-100. PubMed ID: 25539877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
